NCT04623333View on ClinicalTrials.gov

A Study of TQB2450 Injection in Subjects With PD-L1 Positive Recurrent or Metastatic Cervical Cancer

PHASE2UnknownINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

November 30, 2020

Primary Completion Date

December 31, 2022

Study Completion Date

June 30, 2023

Conditions
Recurrent or Metastatic Cervical Cancer
Interventions
DRUG

TQB2450

TQB2450 1200mg administered intravenously (IV) on Day 1 of each 21-day cycle.

Trial Locations (1)

250012

Qilu Hospital of Shandong University, Jinan

Sponsors
All Listed Sponsors
lead

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

INDUSTRY